A5066953061- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Cancer Cells and Metastasis
- Advanced Breast Cancer Therapies
- CAR-T cell therapy research
- Cancer Genomics and Diagnostics
- Ovarian cancer diagnosis and treatment
- Cancer Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Cancer, Stress, Anesthesia, and Immune Response
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Treatments and Mutations
- Bladder and Urothelial Cancer Treatments
- Metastasis and carcinoma case studies
- Estrogen and related hormone effects
The Netherlands Cancer Institute
2016-2024
<h3>Importance</h3> Primary analysis of the TRAIN-2 study showed high pathologic complete response rates after neoadjuvant chemotherapy with or without anthracyclines plus dual<i>ERBB2</i>(formerly<i>HER2</i>) blockade. <h3>Objective</h3> To evaluate 3-year event-free survival (EFS) and overall (OS) an anthracycline-free anthracycline-containing regimen dual<i>ERBB2</i>blockade in patients stage II III<i>ERBB2</i>-positive breast cancer. <h3>Design, Setting, Participants</h3> A total 438...
Abstract Invasive lobular breast cancer (ILC) is the second most common histological subtype, but ILC-specific trials are lacking. Translational research revealed an immune-related ILC subset, and in mouse models, synergy between immune checkpoint blockade platinum was observed. In phase II GELATO trial ( NCT03147040 ), patients with metastatic were treated weekly carboplatin (area under curve 1.5 mg ml –1 min ) as induction for 12 weeks atezolizumab (PD-L1 blockade; triweekly) from third...
The large majority of patients with HER2-positive metastatic breast cancer (MBC) will eventually develop resistance to anti-HER2 therapy and die this disease. Despite, relatively high levels stromal tumor infiltrating lymphocytes (sTILs), PD1-blockade has only shown modest responses. Monalizumab targets the inhibitory immune checkpoint NKG2A, thereby unleashing NK- CD8 T cells. We hypothesized that monalizumab synergizes trastuzumab by promoting antibody-dependent cell-mediated...
1012 Background: Anti-PD(L)1 can result in durable responses patients with metastatic triple negative breast cancer (TNBC). However, only a subgroup of TNBC benefits from anti-PD(L)1 response rates 5-10% unselected cohorts. Strategies to render the tumor micro-environment (TME) more susceptible might include stimulation anti-cancer immune by induction treatment irradiation or low dose chemotherapy. Methods: In stage I (non-comparative Simon's two design) who received ≤ 3 lines palliative...
501 Background: The multicenter phase III TRAIN-2 study showed high pathological complete response (pCR) rates after neoadjuvant chemotherapy with and without anthracylines plus dual HER2-blockade in stage II-III HER2-positive breast cancer patients (67% vs 68%, p = 0.95) (NCT01996267). Here we report 3-year efficacy safety outcomes. Methods: Patients were randomly assigned (1:1) to receive 3 cycles 5-fluoruoracil (500mg/m 2 ), epirubicin (90mg/m cyclophosphamide ) followed by 6 paclitaxel...
<h2>Abstract</h2><h3>Background</h3> The addition of pertuzumab to neoadjuvant trastuzumab-based chemotherapy improves pathologic complete response rates in HER2-positive breast cancer. However, increased toxicity has been reported with the pertuzumab, and this may differ between various backbone regimens. We evaluated toxicities when added either FEC-T (5-fluorouracil, epirubicin, cyclophosphamide, trastuzumab) or weekly paclitaxel, trastuzumab, carboplatin (PTC). <h3>Methods</h3> TRAIN-2...
507 Background: Neoadjuvant chemotherapy with dual HER2 blockade boosts pathologic complete response (pCR) rates in HER2+ breast cancer. The optimal backbone this setting is unknown. We conducted a multicenter phase III trial to study whether anthracyclines would improve outcome compared carboplatin-taxane regimen (NCT01996267). Methods: randomly assigned (1:1) patients stage II-III cancer receive 9 cycles paclitaxel (80mg/m 2 day 1 and 8) carboplatin (AUC = 6mg/ml·min) (arm A) or 3...